316 related articles for article (PubMed ID: 19097497)
1. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
Shastri YM; Povse N; Schröder O; Stein J
Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
[No Abstract] [Full Text] [Related]
2. [Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests].
Malícková K; Janatková I; Bortlík M; Komárek V; Lukás M
Epidemiol Mikrobiol Imunol; 2008 Nov; 57(4):147-53. PubMed ID: 19069028
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin.
Schröder O; Naumann M; Shastri Y; Povse N; Stein J
Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation.
Gearry R; Barclay M; Florkowski C; George P; Walmsley T
N Z Med J; 2005 May; 118(1214):U1444. PubMed ID: 15886739
[No Abstract] [Full Text] [Related]
5. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
[TBL] [Abstract][Full Text] [Related]
6. Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis.
Czub E; Nowak JK; Moczko J; Mankowski P; Lisowska A; Banaszkiewicz A; Banasiewicz T; Walkowiak J
Dev Period Med; 2015; 19(2):167-73. PubMed ID: 26384117
[TBL] [Abstract][Full Text] [Related]
7. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of fecal calprotectin concentration as inflammatory marker in inflammatory bowel diseases in children--preliminary report].
Krzesiek E; Iwańczak B
Pol Merkur Lekarski; 2010 Oct; 29(172):241-6. PubMed ID: 21207640
[TBL] [Abstract][Full Text] [Related]
9. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
10. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.
Kolho KL; Raivio T; Lindahl H; Savilahti E
Scand J Gastroenterol; 2006 Jun; 41(6):720-5. PubMed ID: 16716972
[TBL] [Abstract][Full Text] [Related]
12. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders.
Jeffery J; Lewis SJ; Ayling RM
Inflamm Bowel Dis; 2009 Nov; 15(11):1630-4. PubMed ID: 19462434
[TBL] [Abstract][Full Text] [Related]
13. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
14. Faecal calprotectin: a new marker for Crohn's disease?
Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
[TBL] [Abstract][Full Text] [Related]
16. Review of fecal biomarkers in inflammatory bowel disease.
Sutherland AD; Gearry RB; Frizelle FA
Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
[TBL] [Abstract][Full Text] [Related]
17. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease.
Fagerberg UL; Lööf L; Lindholm J; Hansson LO; Finkel Y
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):414-20. PubMed ID: 18030206
[TBL] [Abstract][Full Text] [Related]
19. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
[TBL] [Abstract][Full Text] [Related]
20. Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome.
Sprakes MB; Hamlin PJ; Ford AC
Am J Gastroenterol; 2011 Jan; 106(1):166; author reply 166-7. PubMed ID: 21212757
[No Abstract] [Full Text] [Related]
[Next] [New Search]